Previously in August 2025, the UK Government responded to announce its intention to implement the Advisory Council on the Misuse of Drugs (ACMD)’s recommendations for the control of named semi-synthetic cannabinoids (SSCs), the generic control of SSCs, and the control of THC precursors (THCAs) as Class B drugs under the Misuse of Drugs Act 1971 (‘the 1971 Act’), Schedule 1 to the Misuse of Drugs Regulations 2001 (‘the 2001 Regulations’) and the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 (‘the 2015 Order’). The ACMD also recommended that the government consult with stakeholders on the generic control proposed for SSCs. On 11 May 2026, the UK Government released a letter to announce its intentions following that consultation. First, to proceed in accordance with the ACMD’s recommendations for the generic control of SSCs. Second, despite a concern that about the potential effect of the control of THCAs on consumer cannabidiol (CBD) products that may contain small quantities of THCAs and other products in what is described as the 'health food/hemp and CBD products sector', the government will proceed with the control of THCAs as Class B named substances under the 1971 Act, Schedule 1 to the 2001 Regulations and the 2015 Order in light of the ACMD evidence on the potential harmfulness of THCAs, (as they can be converted to THC, which is known to have harmful effects, by heating) which are currently unregulated. It noted that in relation to the use of THCAs in research, the government has already set out its intention with respect to research with Schedule 1 drugs in its response of 16 July 2025 to the ACMD’s ‘part 2’ recommendations on barriers to research. It further noted that Consumer CBD products can be exempt from most controls under the 1971 Act if they meet the conditions for exemption under the 2001 Regulations, as set out in the government’s guidance.